Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Elan acquires rights to diazepam gel formulation

June 7, 1996

Trials expected to begin on CoCensys' CCD-1042

June 7, 1996

Pfizer reports neuroleptics

June 7, 1996

Asahi Chem. claims sigma-receptor ligands

June 7, 1996

Transdermal buspirone covered under U.S. patent

June 7, 1996

Compounds with high affinity for 5-HT1A and/or D2 receptors reported by E. Merck

June 7, 1996

CCD-3693 clinical trials scheduled

June 7, 1996

Bristol-Myers Squibb describes compounds with melatonergic properties

June 7, 1996

Pfizer reveals migraine treatment

June 7, 1996

Controlled-release oxycodone HCl now on U.S. shelves

June 7, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for April 15, 2025.
Biopharma exempt from US reciprocal tariffs, but not untouched
BioWorld
At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...
ADPD 2025: Unlocking GLP-1's potential in neurodegeneration
BioWorld
At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...
ADPD 2025: Novel treatment modalities in neurodegenerative disorders
BioWorld Science
The current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease...